Ruth Etzioni

Appointments and Affiliations
 
 
Fred Hutchinson Cancer Research Center
Public Health Sciences Division
Biostatistics Program
Translational & Outcomes Research Group
Full Member, Appointed: 2002
University of Washington
Affilitate Professor, Appointed: 1997
 Professional Headshot of Ruth Etzioni

Mailing Address

Fred Hutchinson Cancer Research Center
1100 Fairview Avenue North
M2-B230
P.O. Box 19024
Seattle, Washington 98109-1024
United States

Contact

Phone: (206) 667-6561
Fax: (206) 667-7264
retzioni@fhcrc.org
http://labs.fhcrc.org/etzioni/index.html
 

Degrees

Ph.D., Carnegie Mellon University, Statistics, 1990.
M.S., Carnegie Mellon University, Statistics, 1987.
B.S., University of Cape Town, Statistics, 1985.

Research Interests

Cancer screening
Methods for evaluating diagnostic tests
Modeling and outcomes research in prostate cancer
Modeling impact of PSA screening and other interventions on prostate cancer incidence and mortality
Costs and benefits of prostate cancer screening
Trends in prostate cancer screening and related behaviors

Dr. Ruth (Douglas) Etzioni is a Full Member in Biostatistics of the Division of Public Health Sciences at the Fred Hutchinson Cancer Research Center. Her work focuses on the development and implementation of statistical methods for prostate cancer studies. In the past, she has worked on assessing the efficacy of PSA screening from population studies, estimating the frequency of overdiagnosis associated with PSA, evaluating novel prostate cancer biomarkers, and tracking patterns and outcomes of prostate cancer care. Her work in prostate cancer surveillance is conducted as part of the Cancer Intervention and Surveillance Modeling Network (CISNET).

As leader of the biostatistics core for the Northwest Prostate Cancer SPORE, Dr. Etzioni has developed methods for analyzing immunohistochemical studies, and combining results from microarray experiments, while working with SPORE investigators to select the most appropriate design and analysis approaches for a broad array of studies. She is an affiliate investigator on the Data Management Coordination Center for the Early Detection Research Network (EDRN) and continues to work with EDRN statisticians on methods for biomarker development. In addition to these projects, her current interests include modeling the development of resistance to androgen ablation therapy.

Memberships

American Statistical Association
Institute of Mathematical Statistics
International Biometric Society
Society for Medical Decision Making

Funding

  • NIH/NCI: Pacific Northwest Prostate Cancer SPORE, Core C: Biostatistics Core (PI), $88,234 (direct), May 1, 2002 to 2012.
  • NIH/NCI: Outcomes Based Guidelines Development for Prostate Cancer Screening and Treatment, $172,221, 2008 to 2012.
  • NIH/NCI: Primary Prevention versus Screening for Prostate Cancer (PI), $178,000 (annual dir, 2003 to 2009.
  • NCI: Modeling US prostate cancer trends: PSA, treatment and risk: Cancer Intervention Surveillance Modeling Network (PI), $153,065 (annual dir, 2000 to 2010.

 

Recent Publications

2013
Ayala, G, Frolov A, Ittman M, Mohammed S, LeBlanc M, Falcon S, Rowley D, Etzioni R.  2013.  Biological correlates of biochemical recurrence free survival using multiple markers in a large tissue microarray cohort.. Annals of clinical and laboratory science. 43(1):11-21. Abstract
Wender, R, Fontham ETH, Barrera E, Colditz GA, Church TR, Ettinger DS, Etzioni R, Flowers CR, Scott Gazelle G, Kelsey DK et al..  2013.  American Cancer Society lung cancer screening guidelines.. CA: a cancer journal for clinicians. 63(2):106-17. Abstract
Gulati, R, Gore JL, Etzioni R.  2013.  Comparative effectiveness of alternative prostate-specific antigen-based prostate cancer screening strategies: model estimates of potential benefits and harms.. Annals of internal medicine. 158(3):145-53. Abstract
Xia, J, Gulati R, Au M, Gore JL, Lin DW, Etzioni R.  2013.  Effects of Screening on Radical Prostatectomy Efficacy: The Prostate Cancer Intervention Versus Observation Trial.. Journal of the National Cancer Institute. Abstract
Etzioni, R, Gulati R, Cooperberg MR, Penson DM, Weiss NS, Thompson IM.  2013.  Limitations of basing screening policies on screening trials: The US Preventive Services Task Force and Prostate Cancer Screening.. Medical care. 51(4):295-300. Abstract
Etzioni, R, Gulati R.  2013.  Response: Reading between the lines of cancer screening trials: using modeling to understand the evidence.. Medical care. 51(4):304-6. Abstract
2012
Mandelblatt, J, Schechter C, Levy D, Zauber A, Chang Y, Etzioni R.  2012.  Building better models: if we build them, will policy makers use them? Toward integrating modeling into health care decisions. Medical decision making : an international journal of the Society for Medical Decision Making. 32(5):656-9.
Xia, J, Trock BJ, Cooperberg MR, Gulati R, Zeliadt SB, Gore JL, Lin DW, Carroll PR, Carter BH, Etzioni R.  2012.  Prostate Cancer Mortality following Active Surveillance versus Immediate Radical Prostatectomy.. Clinical cancer research : an official journal of the American Association for Cancer Research. 18(19):5471-5478. Abstract
Etzioni, R, Gulati R, Tsodikov A, Wever EM, Penson DF, Heijnsdijk EAM, Katcher J, Draisma G, Feuer EJ, de Koning HJ et al..  2012.  The prostate cancer conundrum revisited : Treatment changes and prostate cancer mortality declines.. Cancer. Abstract
Rubinsky, AD, Sun H, Blough DK, Maynard C, Bryson CL, Harris AH, Hawkins EJ, Beste LA, Henderson WG, Hawn MT et al..  2012.  AUDIT-C Alcohol Screening Results and Postoperative Inpatient Health Care Use.. Journal of the American College of Surgeons. 214(3):296-305.e1. Abstract
Gulati, R, Tsodikov A, Wever EM, Mariotto AB, Heijnsdijk EAM, Katcher J, de Koning HJ, Etzioni R.  2012.  The impact of PLCO control arm contamination on perceived PSA screening efficacy.. Cancer causes & control : CCC. 23(6):827-35. Abstract
Zeliadt, SB, Buist DSM, Reid RJ, Grossman DC, Ma J, Etzioni R.  2012.  Biopsy follow-up of prostate-specific antigen tests.. American journal of preventive medicine. 42(1):37-43. Abstract
Etzioni, R, Mucci LA, Chen S, Johansson J-E, Fall K, Adami H-O.  2012.  Increasing use of radical prostatectomy for non-lethal prostate cancer in Sweden.. Clinical cancer research : an official journal of the American Association for Cancer Research. 18(24):6742-6747. Abstract
2011
Williams, LH, Miller DR, Fincke G, Lafrance J-P, Etzioni R, Maynard C, Raugi GJ, Reiber GE.  2011.  Depression and incident lower limb amputations in veterans with diabetes.. Journal of diabetes and its complications. 25(3):175-82. Abstract
Massarweh, NN, Park JO, Bruix J, Yeung RSW, Etzioni R, Symons RG, Baldwin L-M, Flum DR.  2011.  Diagnostic imaging and biopsy use among elderly medicare beneficiaries with hepatocellular carcinoma.. Journal of oncology practice / American Society of Clinical Oncology. 7(3):155-60. Abstract
Gulati, R, Wever EM, Tsodikov A, Penson DF, Inoue LYT, Katcher J, Lee S-Y, Heijnsdijk EAM, Draisma G, de Koning HJ et al..  2011.  What if i don't treat my PSA-detected prostate cancer? Answers from three natural history models. Cancer epidemiology, biomarkers & prevention : a publication of the American Association for Cancer Research, cosponsored by the American Society of Preventive Oncology. 20(5):740-50. Abstract
Zeliadt, SB, Hoffman RM, Etzioni R, Gore JL, Kessler LG, Lin DW.  2011.  Influence of publication of US and European prostate cancer screening trials on PSA testing practices.. Journal of the National Cancer Institute. 103(6):520-3. Abstract
Ramsey, SD, Etzioni R.  2011.  Case-control studies of cancer surveillance procedures.. Journal of clinical epidemiology. 64(1):44.
Gulati, R, Mariotto AB, Chen S, Gore JL, Etzioni R.  2011.  Long-term projections of the harm-benefit trade-off in prostate cancer screening are more favorable than previous short-term estimates.. Journal of clinical epidemiology. 64(12):1412-7. Abstract
2010
Fedewa, SA, Etzioni R, Flanders DW, Jemal A, Ward EM.  2010.  Association of insurance and race/ethnicity with disease severity among men diagnosed with prostate cancer, National Cancer Database 2004-2006.. Cancer epidemiology, biomarkers & prevention : a publication of the American Association for Cancer Research, cosponsored by the American Society of Preventive Oncology. 19(10):2437-44. Abstract
Gulati, R, Inoue L, Katcher J, Hazelton W, Etzioni R.  2010.  Calibrating disease progression models using population data: a critical precursor to policy development in cancer control.. Biostatistics (Oxford, England). 11(4):707-19. Abstract
Zeliadt, SB, Hoffman RM, Etzioni R, Ginger VAT, Lin DW.  2010.  What happens after an elevated PSA test: the experience of 13,591 veterans.. Journal of general internal medicine. 25(11):1205-10. Abstract
Wolf, AMD, Wender RC, Etzioni R, Thompson IM, D'Amico AV, Volk RJ, Brooks DD, Dash C, Guessous I, Andrews K et al..  2010.  American Cancer Society guideline for the early detection of prostate cancer: update 2010.. CA: a cancer journal for clinicians. 60(2):70-98. Abstract
Yu, EY, Gulati R, Telesca D, Jiang P, Tam S, Russell KJ, Nelson PS, Etzioni R, Higano CS.  2010.  Duration of first off-treatment interval is prognostic for time to castration resistance and death in men with biochemical relapse of prostate cancer treated on a prospective trial of intermittent androgen deprivation.. Journal of clinical oncology : official journal of the American Society of Clinical Oncology. 28(16):2668-73. Abstract
Kawachi, MH, Bahnson RR, Barry M, Busby EJ, Carroll PR, Carter BH, Catalona WJ, Cookson MS, Epstein JI, Etzioni R et al..  2010.  NCCN clinical practice guidelines in oncology: prostate cancer early detection.. Journal of the National Comprehensive Cancer Network : JNCCN. 8(2):240-62.